AlphaYou
Overview
Smart money at a glance
Filings to Sep 27, 2026Net selling: insiders sold $9.7M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$9.7M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 26- Open
- $3.40
- 52-wk high
- $5.81
- High
- $3.44
- 52-wk low
- $1.77
- Low
- $3.33
- Prev close
- $3.36
- Mkt cap
- $1.14B
- P/E
- 55.8x
- Volume
- 509.1K
- Fwd P/E
- 10.3x
- Beta
- 1.60
- P/S
- 1.5x
- P/B
- 1.7x
- Profit margin
- +2.1%
- Op margin
- +11.8%
- ROE
- +2.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about GDRX filings
Are insiders buying or selling Goodrx Holdings Inc (GDRX) stock?
Net selling: insiders sold $9.7M and bought $0 of GDRX stock on the open market in the 90 days to Sep 27, 2026, according to SEC Form 4 filings. The largest was Francisco Partners Gp IV, L.P. (10% owner), who sold $9.7M. The latest filing was on Aug 27, 2026.
Which members of Congress have traded GDRX recently?
None. No member of Congress disclosed a GDRX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this GDRX smart-money data?
This summary uses filings available on Sep 27, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What insiders are doing
How top traders are positioned
No tracked top-trader positions in GDRX right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings landed in line with what analysts expected.
Earnings per share
$0.04 expected
Reports Nov 3, 2026, in 37 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $196.0M | $194.8M | $194.0M | $200.4M |
| Cost of what it sold | $13.4M | $17.5M | $41.9M | $21.0M |
| Gross profit | $182.6M | $177.3M | $152.1M | $179.4M |
| What it spent | ||||
| Research and development | $31.0M | $28.9M | $30.2M | $26.7M |
| Sales and admin | $32.0M | $23.9M | $26.8M | $24.8M |
| Other operating costs | $105.0M | $101.8M | $75.5M | $104.3M |
| Total operating expenses | $168.0M | $154.6M | $132.5M | $155.8M |
| What was left | ||||
| Operating profit | $14.6M | $22.7M | $19.5M | $23.6M |
| Interest on debt | $10.8M | $10.4M | $9.8M | $9.8M |
| Profit before tax | $6.1M | $14.2M | $5.6M | $15.5M |
| Tax | $5.0M | $8.8M | $4.5M | $6.9M |
| Net profit | $1.1M | $5.4M | $1.2M | $8.5M |
| EBITDA | $38.4M | $47.7M | $37.2M | $25.3M |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace